Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | smad | 0.001 | 0 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0852 | 0.1286 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.656 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0852 | 0.1286 | 0.5 |
Schistosoma mansoni | smad1 5 8 and | 0.001 | 0 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.656 | 1 | 0.5 |
Schistosoma mansoni | TGF-beta signal transducer Smad2 | 0.001 | 0 | 0.5 |
Echinococcus multilocularis | Smad4 | 0.001 | 0 | 0.5 |
Echinococcus multilocularis | mothers against decapentaplegic 5 | 0.001 | 0 | 0.5 |
Echinococcus granulosus | TGF beta signal transducer SmadC | 0.001 | 0 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.656 | 1 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.0205 | 1 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.656 | 1 | 0.5 |
Echinococcus multilocularis | smad | 0.001 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.656 | 1 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.0205 | 1 |
Echinococcus granulosus | mothers against decapentaplegic 5 | 0.001 | 0 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0852 | 0.1286 | 0.5 |
Schistosoma mansoni | smad1 5 8 and | 0.001 | 0 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.0205 | 1 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.656 | 1 | 0.5 |
Schistosoma mansoni | smad | 0.001 | 0 | 0.5 |
Schistosoma mansoni | smad1 5 8 and | 0.001 | 0 | 0.5 |
Echinococcus multilocularis | TGF beta signal transducer SmadC | 0.001 | 0 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0852 | 0.1286 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0852 | 0.1286 | 0.5 |
Schistosoma mansoni | Smad4 | 0.001 | 0 | 0.5 |
Echinococcus granulosus | Smad4 | 0.001 | 0 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.656 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 17.7828 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.